FY2025 Earnings Estimate for Neogen Issued By Zacks Research

Neogen Co. (NASDAQ:NEOG) – Stock analysts at Zacks Research lowered their FY2025 earnings estimates for Neogen in a research report issued on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.39 per share for the year, down from their prior forecast of $0.45. The consensus estimate for Neogen’s current full-year earnings is $0.41 per share. Zacks Research also issued estimates for Neogen’s Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.13 EPS, Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.15 EPS and FY2027 earnings at $0.58 EPS.

A number of other analysts also recently commented on the company. Piper Sandler reissued a “neutral” rating and issued a $13.00 price objective (down previously from $16.50) on shares of Neogen in a research note on Tuesday, January 21st. Guggenheim began coverage on shares of Neogen in a report on Thursday, December 19th. They issued a “buy” rating and a $15.00 price target for the company.

Neogen Price Performance

NASDAQ NEOG opened at $11.46 on Friday. The firm has a market capitalization of $2.49 billion, a PE ratio of -5.23 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. Neogen has a 12 month low of $10.72 and a 12 month high of $18.58. The company’s 50 day simple moving average is $12.45 and its 200 day simple moving average is $14.68.

Neogen (NASDAQ:NEOG) last announced its quarterly earnings results on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.12. The company had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. Neogen’s revenue was up .7% compared to the same quarter last year. During the same quarter last year, the business earned $0.11 earnings per share.

Hedge Funds Weigh In On Neogen

Hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its holdings in Neogen by 142.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after purchasing an additional 1,165 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Neogen by 196.7% in the fourth quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock valued at $41,000 after acquiring an additional 2,233 shares during the period. Neo Ivy Capital Management bought a new position in Neogen during the third quarter worth $66,000. KBC Group NV increased its holdings in shares of Neogen by 39.1% during the 4th quarter. KBC Group NV now owns 8,464 shares of the company’s stock worth $103,000 after purchasing an additional 2,379 shares during the period. Finally, Marco Investment Management LLC acquired a new position in shares of Neogen during the third quarter valued at about $169,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Insider Buying and Selling

In related news, CEO John Edward Adent purchased 23,035 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the acquisition, the chief executive officer now owns 269,164 shares in the company, valued at $2,968,878.92. This trade represents a 9.36 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David H. Naemura purchased 14,800 shares of the stock in a transaction dated Thursday, January 16th. The shares were bought at an average price of $11.11 per share, for a total transaction of $164,428.00. Following the completion of the acquisition, the chief financial officer now owns 61,434 shares in the company, valued at $682,531.74. This represents a 31.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by company insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.